Now I have a good calibration picture. Let me write the final review.

Final calibration assessment:
- "Revisiting Scaling Effects" (avg 4.0, Reject): Similar medical scaling focus, had a critical methodological concern (clinical rigor), no confidence intervals → Reject. Our paper has a more central flaw (confounded comparison) but a genuinely novel finding (safety collapse) that the other paper lacks. Comparable quality level.
- "Training Mice to Compete with Elephants" (avg 6.0, Accept): Well-executed with comprehensive experiments. Our paper is clearly below this bar due to the confounded comparison and undefined metrics.
- "SciSafeEval" (avg 4.5, Reject): Benchmark paper with methodological concerns.

Based on these anchors, the paper sits in the 3.5–4.5 range. I'll assign **4.0** (borderline reject).

Here is my final review:

## Summary
This paper evaluates small language models (SLMs, ≤3B params) and small vision-language models against larger medical-domain-adapted counterparts on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). It claims that fine-tuned small LMs can match or exceed larger medical LLMs, identifies a "safety collapse" threshold around 1B parameters where hallucination rates spike dramatically, and finds that small VLMs still lag behind larger ones.

## Strengths

- **The "Safety Collapse" concept (Table 3) is a concrete and practically useful finding.** Identifying a sharp degradation threshold around 1B parameters—where hallucination rates spike from 2–3% to 18–75%—provides actionable guidance for deployment decisions. The granularity across four dimensions (task adherence, hallucination rate, concept recall, prompt robustness) goes beyond typical single-metric reporting.

- **Multi-metric evaluation design is appropriate for the question.** Using BLEU, ROUGE-L, BERTScore, and MEDCON (UMLS concept matching) to capture syntactic, semantic, and clinical-concept dimensions separately is well-suited to the clinical summarization task.

- **The paper tests both in-context learning and fine-tuning regimes**, giving a fuller picture than either alone. The contrast between ICL and LoRA results is informative even if the comparison is confounded (see Weaknesses).

## Weaknesses

### Fatal
None.

### Major

- **The paper's central claim rests on a confounded comparison: fine-tuned small models vs. non-fine-tuned large models.** The abstract states that "multiple small models not only reach but occasionally exceed the performance of much larger medical LLMs," and the Results section (line 231) states "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric." However, inspecting Figure 3 reveals that the large models (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) have only In-Context Learning (ICL) scores—they were **never fine-tuned with LoRA**. The paper compares fine-tuned small models against non-fine-tuned large models, confounding model size with adaptation method. The headline claim is only supported under unequal treatment. This is a structural issue that undermines the paper's primary conclusion. To make a valid comparison, the large models would need the same LoRA treatment. (Verified: Figure 3 shows no LoRA column for large models; the paper only applies PEFT to small LMs, per line 120: "we applied three parameter-efficient fine tuning methods…to each small LLM.")

- **The Collapse Analysis metrics (Table 3) are undefined.** The paper reports "Task Adherence," "Concept Recall," "Prompt Robustness," and a composite "Readiness Score" without any formulas, rubrics, or algorithmic definitions. These metrics are central to the paper's claimed contributions 2 and 3 (granular collapse evaluation and definition of minimum viable scale), yet a reader cannot replicate them or assess their validity. (Verified: lines 114–115 list the dimensions but provide no operational definitions.)

### Minor

- **No measures of variance or statistical significance.** All scores are point estimates on 250 test samples (MeQSum) with no confidence intervals, standard deviations, or significance tests. Given that some differences are small (e.g., BERTScore of 0.9007 vs. 0.8938 in Table 2), readers cannot judge whether these differences are reliable or within evaluation noise. This is a standard expectation for benchmarking papers.

- **Zero-shot results (Table 2) are more nuanced than the framing suggests.** The abstract's claim that small models "occasionally exceed" large ones in zero-shot is technically true (SmolLM2 leads on ROUGE-L and BERTScore) but the overall picture is mixed: BioMistral leads on BLEU (0.0690) and OpenBioLLM leads on MEDCON (0.336). The paper's broader narrative underplays this nuance.

- **Fine-tuning hyperparameters are absent.** The paper introduces LoRA/QLoRA mathematically (Eq. 1) but reports no rank, alpha, target modules, learning rate, number of epochs, or batch size. This makes the fine-tuning experiments unreproducible.

- **Gemma-3-4b-it (4B) exceeds the stated 3B parameter cap.** Line 76 states "We considered only SLMs with a maximum of 3 billion parameters," but Table 3 includes Gemma-3-4b-it at 4B parameters. While this model is used for the intra-family scaling analysis, the inconsistency should be clarified.

- **SmolLM3-3B appears in Table 3 without introduction.** Table 1 lists only "SmolLM Family" and the paper cites SmolLM2 (Allal et al., 2025). The appearance of "SmolLM3-3B" in Table 3 is unexplained.

- **The test set of 250 samples** for each dataset is small, and the paper does not justify this size or state whether it is the full test split or a subsample.

### Trivial
None.

## Nice-to-Haves

- **Add the missing comparison:** Fine-tune the large medical models (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) with the same LoRA setup used for the small models. If small models still match or exceed large ones under equal treatment, the claim is genuinely strong. If not, the paper's honest contribution is that fine-tuning matters more than model size—still useful, but a different finding.

- **Define the Collapse Analysis metrics** with explicit formulas or scoring rubrics for Task Adherence, Concept Recall, Prompt Robustness, and the composite Readiness Score.

- **Report confidence intervals** (e.g., bootstrapped estimates) for the main comparisons, especially where metric differences are small.

- **Fine-tuning details** (LoRA rank, alpha, learning rate, epochs, batch size) should be reported.

## Removed Points
These points were flagged by the reviewer but are removed/reduced per filtering rules:

- *"VLM conclusions are unsurprising/near-tautological"* — The paper honestly reports a negative result (small VLMs lag behind) and offers reasonable architectural explanations (vision encoders, fusion strategies). An unsurprising but valid empirical result is not a weakness.
- *"Decoding parameters not justified"* — The paper provides a brief justification (line 78: "strike a balance between fidelity and variability").
- *"Related work is thin"* — Removed per instruction to not criticize missing related work.
- *"Missing checkpoint versions/commit hashes"* — Trivial reproducibility nitpick.
- *"MeQSum is a single dataset"* — The paper acknowledges this limitation (lines 268–270).
- *"No human evaluation"* — Reasonable but not standard for a paper of this scope/type; better as a nice-to-have.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions

1. **Run the missing experiment:** Fine-tune all large medical LMs with LoRA and compare all models under equal treatment. This single addition would either validate the paper's central claim or reveal a more nuanced truth about the relative importance of fine-tuning vs. model size.
2. **Define the Collapse Analysis metrics** with algorithmic precision. The "Readiness Score" composite in particular needs a formula.
3. **Add confidence intervals** or bootstrapped variance estimates for all reported metrics.
4. **Clarify the Gemma-3-4b-it inclusion** relative to the 3B parameter constraint, and introduce SmolLM3-3B if it is a distinct model.
5. **Report fine-tuning hyperparameters** (LoRA rank, alpha, learning rate, epochs) for reproducibility.

## Score and Decision

**Round 1 bracket:** 3.5–4.5 (based on comparison with clinical NLP evaluation papers in the 3.0–5.0 range from calibration search, where similar methodological concerns led to Reject decisions).

**Anchor papers used in calibration:**

| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| /home/wg25r/split_review_opus_repro/datasets/deepreview_13k_calibration/jgVqCCg5XX.md | 4.00 | R1, R2 | Similar medical scaling topic; rejected primarily for clinical rigor concerns and lack of confidence intervals. Our paper has a more central flaw (confounded comparison) but a more novel finding (safety collapse). Roughly comparable quality. |
| /home/wg25r/split_review_opus_repro/datasets/deepreview_13k_calibration/eENHKMTOfW.md | 6.00 | R1 | Small model fine-tuning guide; accepted with comprehensive experiments. Our paper is clearly below this bar due to the confounded comparison and undefined metrics. |
| /home/wg25r/split_review_opus_repro/datasets/deepreview_13k_calibration/Kz3yckpCN5.md | 7.00 | R1 | Well-executed study on model imitation; accepted. More rigorous methodology than our paper. |
| /home/wg25r/split_review_opus_repro/datasets/deepreview_13k_calibration/MEztAJjcYZ.md | 4.25 | R1 | Clinical note summarization paper; rejected with mixed reviews (3,3,8,3). |
| /home/wg25r/split_review_opus_repro/datasets/deepreview_13k_calibration/gYcft1HIaU.md | 4.33 | R2 | Clinical knowledge evaluation; rejected with scores 5,5,3. |

The paper asks an important question and introduces a genuinely useful concept (the "safety collapse" threshold), but its central claim is undermined by a confounded experimental comparison, and its novel evaluation metrics are left undefined. The safety collapse analysis is the strongest contribution and is independent of the confounded comparison, but the paper's framing centers on the unsupported small-vs-large claim. In its current form, the paper does not support its stated contributions sufficiently for acceptance.

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>